Zobrazeno 1 - 10
of 294
pro vyhledávání: ''
Autor:
Jane R. Kenny, Mathew Williams, Richard Beasley, A. Mcgregor, Maria E. Wilson, Avi Eliahu, Irene Braithwaite, Matthew R. Durk, Jennifer Tom, Fang Cai, Ryan Owen, Joshua Galanter, Hart S. Dengler, Rui Zhu, Mark Zak, Hubert Chen
Publikováno v:
Journal of Allergy and Clinical Immunology. 148:783-789
Background The Janus kinase (JAK) pathway mediates the activity of many asthma-relevant cytokines, including IL-4 and IL-13. GDC-0214 is a potent, inhaled, small-molecule JAK inhibitor being developed for the treatment of asthma. Objective We sought
Autor:
Amy D. Klion, Florence Roufosse, Marc E. Rothenberg, Suyong Yun Kirby, Jane H Bentley, Jonathan Steinfeld, Martyn J. Gilson, Eric S. Bradford, Steven W. Yancey, Andrew J. Wardlaw, Jean-Emmanuel Kahn, Gerald J. Gleich
Publikováno v:
Journal of Allergy and Clinical Immunology
Journal of Allergy and Clinical Immunology, Elsevier, 2020, 146 (6), pp.1397-1405. ⟨10.1016/j.jaci.2020.08.037⟩
Journal of allergy and clinical immunology
Journal of Allergy and Clinical Immunology, Elsevier, 2020, 146 (6), pp.1397-1405. ⟨10.1016/j.jaci.2020.08.037⟩
Journal of allergy and clinical immunology
Background: Anti–IL-5 therapy is a potential treatment for patients with hypereosinophilic syndrome (HES), although its clinical efficacy is unclear. Objective: We sought to investigate the clinical efficacy and safety of mepolizumab versus placebo
Autor:
Theodore A. Omachi, L. Islam, Claus Bachert, Rui Zhu, Philippe Gevaert, Jonathan Corren, Monica Ligueros-Saylan, Joseph K. Han, Joaquim Mullol, Kit Wong, Ryan Owen, Derrick Kaufman, Monet Howard, Stella E. Lee
Publikováno v:
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by IgE hyperproduction and eosinophilic inflammation. The anti-IgE antibody, omalizumab, has demonstrated efficacy in patients with CRSwNP and comorbid asthma previously.
Autor:
Jean-David Bouaziz, Grazyna Pulka, Jonathan I. Silverberg, Andreas Pinter, Andreas Wollenberg, Dedee F. Murrell, Christophe Piketty, Alan Clucas, Yves Poulin, Lisa Lindsey, Andrew F Alexis, Faiz Ahmad
Publikováno v:
Journal of Allergy and Clinical Immunology. 145:173-182
Background: Nemolizumab targets the IL-31 receptor a subunit involved in atopic dermatitis (AD) pathogenesis. Objective: We sought to evaluate a new dosing strategy of nemolizumab in patients with AD. Methods: We performed a 24-week, randomized, doub
Autor:
James G. Krueger, Usman Chaudhry, Hitokazu Esaki, Neil M.H. Graham, Maria Suprun, Jonathan I. Silverberg, Marius Ardeleanu, Xiangyu Peng, Yeriel Estrada, Hui Xu, Robert Bissonnette, Brian N. Swanson, Gianluca Pirozzi, Rick Zhang, Emma Guttman-Yassky, Mayte Suárez-Fariñas, Jennifer D. Hamilton, Alan Menter, George D. Yancopoulos, Benjamin Ungar
Publikováno v:
Journal of Allergy and Clinical Immunology. 143:155-172
Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key drivers of type 2-driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases.This placebo-controlled, double-blind trial (NCT01979016
Autor:
Joaquim Mullol, Joseph K. Han, Rui Zhao, Kit Wong, Randall A. Ow, Monet Howard, L. Islam, Claus Bachert, Monica Ligueros-Saylan, Theodore A. Omachi, Stella E. Lee, Jonathan Corren, R. Saenz, Philippe Gevaert
Publikováno v:
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently remains uncontrolled despite maximal medical therapy and sinonasal surgery, presenting several unmet needs and challenges. Omalizumab previously demonstrated efficacy in CRSwNP
Autor:
Jianping Zhao, Jing Liu, Fankai Meng, Gaoxiang Wang, Liang Zou, Tiebin Jiang, Jungang Xie, Xiaoxi Zhou, Yang Cao, Jia Wei, Liting Chen, Na Wang, Wei Wang, Jianfeng Zhou, Zekai Mao, Hui Cheng, Gang Huang, Liang Huang, Hui Luo, Xing Chen, Lifang Huang
Publikováno v:
Journal of Allergy and Clinical Immunology
The Journal of Allergy and Clinical Immunology
The Journal of Allergy and Clinical Immunology
Background Accumulating evidence proposed JAK inhibitors as therapeutic targets warranting rapid investigation. Objective This study evaluated the efficacy and safety of ruxolitinib, a Janus-associated kinase (JAK1/2) inhibitor, for COVID-19. Methods
Autor:
Qing Li, Richard F. Lockey, Giorgio Walter Canonica, Amarjot Kaur, David P. Skoner, Michael S. Blaiss, Albrecht Bufe, Hendrik Nolte, Jens Strodl Andersen, Joseph G. Ibrahim
Publikováno v:
J Allergy Clin Immunol
Background Large sample sizes are needed for sublingual immunotherapy (SLIT) trials because of inherent data variability secondary to inconsistent allergen exposure. Obtaining large sample sizes for pediatric SLIT trials is challenging, but a Bayesia
Publikováno v:
Journal of Allergy and Clinical Immunology. 140:431-436
Background Pharmacodynamic assessment of the systemic effect of inhaled corticosteroids (ICSs) is often done by measuring 24-hour urine free cortisol (UFC) excretion. Knemometry assessing short-term lower-leg growth rate (LLGR) is a more rarely used
Autor:
Gary T. Ferguson, William W. Busse, Eugene R. Bleecker, J. Mark FitzGerald, Richard F. Olsson, Laura Brooks, Peter Barker, Bora study investigators, Mitchell Goldman, Ubaldo J. Martin
Publikováno v:
Journal of Allergy and Clinical Immunology. 148:266-271.e2
Background Adults and adolescents with severe asthma who completed the 48-week SIROCCO and 56-week CALIMA phase III benralizumab trials entered the safety extension study BORA (NCT02258542). The continued safety and efficacy of benralizumab in the fi